Antigen-specific regulatory T cell therapy for alzheimer's disease
Engineered regulatory T cells (Tregs) expressing an amyloid-beta-specific T cell receptor (TCRAb-Tregs) for targeted treatment of Alzheimer's disease. The approach uses CRISPR-Cas9 gene editing to confer Aβ antigen specificity, enabling Tregs to access amyloid-rich brain regions, reduce plaque burden, modulate microglial responses, and improve cognitive outcomes in preclinical AD models.
Overview
This solution addresses a critical unmet need in Alzheimer's disease (AD) therapeutics by engineering antigen-specific regulatory T cells (Tregs) that can target amyloid-beta (Aβ)-rich regions in the brain. While Tregs are well known for maintaining immune tolerance and offering neuroprotective potential, their lack of defined antigen specificity has limited their therapeutic application in neurodegenerative diseases. By conferring Aβ antigen specificity through a transgenic T cell receptor (TCRAβ), these engineered Tregs can selectively home to disease sites in the brain, reduce amyloid plaque burden, transform T effector cell responses, and reverse disease-associated neurotoxicity. This approach represents a fresh directive beyond traditional immunization-based disease-modifying therapies that have faced limitations and safety concerns.
Technical specifications
Core technology:
- TCR-engineered Tregs generated by CRISPR-Cas9 knockout of the endogenous TCR and incorporation of a transgenic TCRAβ identified from Aβ-specific clonal T effector cells
- Antigen-specific targeting enables Treg migration to amyloid-rich brain regions
- Mechanism involves reduction of reactive microglia numbers and modulation of microglial composition
- Concomitant increase in amyloid plaque clearance and improved cognitive outcomes in APP/PS1 mouse models
- Comparison against polyclonal Tregs and dysfunctional Treg controls to validate specificity
Evaluation methods:
- Immunohistochemistry to assess Treg-mediated effects on amyloid plaque deposition
- Thioflavin-S staining to quantify brain area occupied by dense amyloid plaques
- Measurement of soluble and insoluble Aβ fragments in cortex and hippocampus
- Behavioral and motor function assessments linked to microglial reactions
Technology readiness level
The technology has been validated in early preclinical studies using the APP/PS1 Alzheimer's disease mouse model. Initial results demonstrate that TCRAβ-Tregs successfully target the brain, reduce reactive microglia, increase amyloid plaque clearance, and improve cognitive outcomes. Future validation plans include comprehensive evaluation of TCR-Aβ-Treg effects on amyloid burden in cortex and hippocampus, assessment of both soluble and insoluble Aβ fragment reduction, and detailed analysis of dense plaque deposition in the hippocampus compared to polyclonal Treg and dysfunctional Treg controls. The approach is positioned for further translational development toward clinical application.
About University of Nebraska Medical Center
The University of Nebraska Medical Center is a public academic health sciences center in Omaha with a statewide footprint, uniting education, research, and patient care through an integrated hospital partnership. Co‑located clinical and research facilities provide access to patients, data, and specimens, while shared cores, advanced simulation, and centralized clinical trial support speed translation. A regional care network across Nebraska and the central U.S. provides recruitment and real‑world deployment sites, and Omaha’s health and biotech ecosystem eases collaboration and scale‑up. Research is backed by the National Institutes of Health and other U.S. agencies, and a dedicated tech transfer office manages IP, licensing, startups, and industry‑sponsored agreements.
delivered to your inbox.